Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis
Sponsor: Vanda Pharmaceuticals
Listed as NCT04028492, this PHASE3 trial focuses on Diabetic Gastroparesis and Gastroparesis and remains completed. Sponsored by Vanda Pharmaceuticals, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Apr 2024 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
▶ Show 4 earlier versions
-
Apr 2023 — Oct 2023 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Apr 2021 — Apr 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Aug 2019 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vanda Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .